Healthcare vs. legal MSO roll-ups: same playbook, different inning

Unless marked as sourced, the views in this article are my own, from leading M&A at GI Alliance in 2023–24 and now at Commonwealth Island Capital, a legal MSO platform.

Two markets, two speeds

Healthcare MSO consolidation is mature. A study published in Health Affairs, summarized by Becker’s Hospital Review, counted 816 private equity-acquired physician practice sites in 2012 and 5,779 in 2021, roughly a 600% increase. By 2021, PE-backed groups held more than 30% market share in at least one specialty in 120 of 384 metropolitan areas, and more than 50% in 60 of those. The study recorded 317 acquisitions across ten specialties in 2021 alone.

Legal is at the other end of the curve. Holland & Knight, one of the most active law firms advising on these transactions, reported closing 7 law firm MSO deals in 2025 and being on track for 27 in 2026, with roughly 70 transactions in its pipeline as of April 2026. That is meaningful momentum for a market that barely existed three years ago, and still a rounding error next to physician practices.

The gold standard: GI Alliance

GI Alliance is the clearest example of what a physician MSO roll-up looks like when it works. The milestones, from Becker’s ASC Review and Cardinal Health’s filings:

From formation to strategic exit took a little over six years. The valuation moved from $2.2B to $3.9B in about two and a half years after the 2022 recapitalization, a period in which I led 23 of the platform’s transactions.

Legal MSOs at inning zero

Sourced data points on where legal stands in 2026:

• Platforms are forming. Uplift Investors launched Orion Legal in January 2026 alongside Dudley DeBosier (Louisiana), then added Hughes & Coleman (Kentucky) in May, John Foy & Associates (Georgia) in June and Bottaro Injury Lawyers (Rhode Island) in July.
• Valuations are being set. Rafi Law Group (Arizona) received $125M from an outside investor in April 2026, with its MSO valued at roughly $450M, reported as the largest publicly disclosed deal of its kind.
• The biggest names are testing the water. Morgan & Morgan reportedly hired J.P. Morgan to explore selling a minority stake at a potential valuation above $1B; no deal had been finalized as of August 2026.
• Interest is broadening. Holland & Knight attorneys report MSO interest expanding beyond personal injury to firms of all sizes, practice areas and geographies.

In baseball terms, healthcare is in the late innings. Legal has barely taken the field.

How the structures map

The two models are built on the same idea: investors cannot own the professional practice, so they own the business around it.

Where the analogy breaks

My view. The structure transfers cleanly. The economics do not, and buyers who assume they do will overpay:

• Revenue is contingent. A GI practice bills for procedures it performed last month. A PI firm is paid when cases resolve, sometimes years later. Case inventory is the balance sheet, and trailing EBITDA can mislead in either direction.
• No payer leverage. Physician platforms create value partly by negotiating with insurers at scale. Legal platforms have no equivalent counterparty. The scale benefits come from marketing efficiency, intake conversion and operations.
• Fee design is stricter. Healthcare MSAs have more room on fee mechanics in many states. In legal, anything that looks like a share of legal fees is the fastest way to fail an ethics review.
• Different regulators. Healthcare buyers watch CMS, state attorneys general and new state ownership laws. Legal buyers answer to state bars and state supreme courts, where the rules are older, less tested against MSOs and vary sharply by state.
• Different sellers. Trial lawyers negotiate like trial lawyers. Expect the seller to be the best negotiator in the room.

What I would carry over from GI Alliance

My view. The lessons from the gold standard that matter most at inning zero:

1. Producer-led governance wins recruiting. GI Alliance stayed physician-led through its recapitalization. Legal platforms that let attorneys feel they are joining a firm rather than selling to a fund will win the best practices.
2. Anchor, then densify. A respected anchor practice in a strong market, followed by add-ons that build regional density, beats scattered acquisitions.
3. Integration is the product. The value is created after close: centralized operations, shared technology, intake and reporting. Sellers can tell which buyers have done this before.
4. Build ancillaries deliberately. In GI, ASC ownership changed platform economics. Legal will have its equivalents, and the first platforms to build them inside the rules will compound fastest.
5. Template discipline compounds. Standard LOIs, services agreements, diligence checklists and funds flows let a platform close its 20th deal faster than its 2nd.

Having seen how the physician roll-up story ends, the most interesting seat is at the start of the next one. In legal, the templates are still being written, and the buyers writing them now will set the market.

Frequently asked questions

Louie Lee
Founder & Managing Partner, Lockstep Partners. Led M&A at six PE-backed healthcare and legal services platforms; previously Greenhill & Co., UBS and Graham Partners. Get in touch.

This article is general information, not legal, tax or investment advice. Laws change quickly; confirm current requirements with counsel in each state.